Researchers at University of Florida Detail Findings in Vaccines (Dependency of Vaccine Efficacy on Pre-Exposure and Age: A Closer Look at a Tetravalent Dengue Vaccine)
By a News Reporter-Staff News Editor at Vaccine Weekly Fresh data on Immunization - Vaccines are presented in a new report. According to news reporting originating from Gainesville, Florida, by NewsRx correspondents, research stated, "A recombinant, live-attenuated, tetravalent dengue vaccine (CYD-TDV) was licensed for children of 9 years old or older in a few countries, but the dependence of vaccine efficacy on baseline immunity status and age groups has not been fully characterized. Combining the two phase III trials, CYD14 and CYD15, we estimated the vaccine efficacy for each of the four serotypes of dengue virus (DENV), as well as all serotypes combined, simultaneously stratified by baseline immunity status and age group, while accounting for uncertainty in the baseline immunity status of subjects."
Our news editors obtained a quote from the research from the University of Florida, "Baseline seropositive subjects showed high efficacy for all serotypes, 70.2% (95% confidence interval [CI]: 57.4, 80.1) for dengue 1 (DENV-1), 67.9% (95% CI: 49.9, 82.0) for DENV-2, 77.5% (95% CI: 64.3, 90.2) for DENV-3, 89.9% (95% CI: 79.8, 99.9) for DENV-4, and 75.4% (95% CI: 68.3, 81.6) overall. In contrast, baseline seronegative subjects showed moderate efficacy against DENV-4, 51.2% [95% CI: 20.0, 72.8] but no significant efficacy against other serotypes. Among seropositive children, the overall efficacy tended to increase with age, 35.9% (95% CI: -7.6, 69.3) for children less than or equal to5 years old, 65.6% (95% CI: 40.3, 84.2) for 6 -8 years old, 73.4% (95% CI: 62.6, 82.1) for 9 -11 years old, and 80.6% (95% CI: 72.9, 87.3) for 12 years or older. The CYD-TDV vaccine was highly efficacious for all dengue serotypes among children older than 5 years who have acquired baseline immunity from previous exposure."
According to the news editors, the research concluded: "Increasing vaccine efficacy with age was not fully explained by increasing prevalence of baseline immunity with age."
For more information on this research see: Dependency of Vaccine Efficacy on Pre-Exposure and Age: A Closer Look at a Tetravalent Dengue Vaccine. Clinical Infectious Diseases, 2017;():. (Oxford University Press - www.oup.com/; Clinical Infectious Diseases - cid.oxfordjournals.org)
The news editors report that additional information may be obtained by contacting Y. Yang, Dept. of Biostatistics and Emerging Pathogens Institute, University of Florida, Gainesville, FL, United States. Additional authors for this research include Y. Meng, M.E. Halloran and I.M Longini (see also Immunization - Vaccines).
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1093/cid/cix766. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
Keywords for this news article include: Florida, Pediatrics, Gainesville, RNA Viruses, Dengue Fever, Immunization, United States, Vaccine Efficacy, Biological Products, Arbovirus Infections, RNA Virus Infections, Flavivirus Infections, Flaviviridae Infections, Mosquito Borne Diseases, Dengue Hemorrhagic Fever, Viral Hemorrhagic Fevers, North and Central America.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC